TY - JOUR
T1 - Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma
AU - Latenstein, Anouk E. J.
AU - van der Geest, Lydia G. M.
AU - Bonsing, Bert A.
AU - Koerkamp, Bas Groot
AU - Mohammad, Nadia Haj
AU - de Hingh, Ignace H. J. T.
AU - de Meijer, Vincent E.
AU - Molenaar, Izaak Q.
AU - van Santvoort, Hjalmar C.
AU - van Tienhoven, Geertjan
AU - Verheij, Joanne
AU - Vissers, Pauline A. J.
AU - de Vos-Geelen, Judith
AU - Busch, Olivier R.
AU - van Eijck, Casper H. J.
AU - van Laarhoven, Hanneke W. M.
AU - Besselink, Marc G.
AU - Wilmink, Johanna W.
AU - Dutch Pancreatic Canc Grp
PY - 2020/1
Y1 - 2020/1
N2 - Background: In recent years, new treatment options have become available for pancreatic ductal adenocarcinoma (PDAC) including 5-fluorouracil, leucovorin, irinotecan and oxaliplatin. The impact hereof has not been assessed in nationwide cohort studies. This population-based study aimed to investigate nationwide trends in incidence, treatment and survival of PDAC.Materials and methods: Patients with PDAC (1997-2016) were included from the Netherlands Cancer Registry. Results were categorised by treatment and by period of diagnosis (1997-2000, 2001-2004, 2005-2008, 2009-2012 and 2013-2016). Kaplane-Meier survival analysis was used to calculate overall survival.Results: In a national cohort of 36,453 patients with PDAC, the incidence increased from 12.1 (1997-2000) to 15.3 (2013-2016) per 100,000 (p <0.001), whereas median overall survival increased from 3.1 to 3.8 months (p <0.001). Over time, the resection rate doubled (8.3% -16.6%, p-trendConclusion: The incidence of PDAC increased in the past two decades. Resection rates and use of adjuvant or palliative chemotherapy increased with improved survival in these patients. In all patients with PDAC, however, the survival benefit of 3 weeks is negligible because the majority of patients only received supportive care. (C) 2019 The Authors. Published by Elsevier Ltd.
AB - Background: In recent years, new treatment options have become available for pancreatic ductal adenocarcinoma (PDAC) including 5-fluorouracil, leucovorin, irinotecan and oxaliplatin. The impact hereof has not been assessed in nationwide cohort studies. This population-based study aimed to investigate nationwide trends in incidence, treatment and survival of PDAC.Materials and methods: Patients with PDAC (1997-2016) were included from the Netherlands Cancer Registry. Results were categorised by treatment and by period of diagnosis (1997-2000, 2001-2004, 2005-2008, 2009-2012 and 2013-2016). Kaplane-Meier survival analysis was used to calculate overall survival.Results: In a national cohort of 36,453 patients with PDAC, the incidence increased from 12.1 (1997-2000) to 15.3 (2013-2016) per 100,000 (p <0.001), whereas median overall survival increased from 3.1 to 3.8 months (p <0.001). Over time, the resection rate doubled (8.3% -16.6%, p-trendConclusion: The incidence of PDAC increased in the past two decades. Resection rates and use of adjuvant or palliative chemotherapy increased with improved survival in these patients. In all patients with PDAC, however, the survival benefit of 3 weeks is negligible because the majority of patients only received supportive care. (C) 2019 The Authors. Published by Elsevier Ltd.
KW - BODY
KW - CANCER SURGERY
KW - CENTRALIZATION
KW - CHEMOTHERAPY
KW - Epidemiology
KW - GEMCITABINE
KW - IMPACT
KW - Incidence
KW - PANCREATICODUODENECTOMY
KW - Pancreatic cancer
KW - RESECTION
KW - Survival
KW - EPIDEMIOLOGY
U2 - 10.1016/j.ejca.2019.11.002
DO - 10.1016/j.ejca.2019.11.002
M3 - Article
C2 - 31841792
VL - 125
SP - 83
EP - 93
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
ER -